DNLI
DNLI
NASDAQ · Biotechnology

Denali Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$24.05
+0.74 (+3.17%)
As of Jun 22, 9:58 PM ET ·
Analyst Consensus
Strong Buy
25
Analysts
High
Coverage
Buy 23 92%
Hold 2 8%
Sell 0 0%
Price Target
Analyst Price Target +218.3% upside
Low Target $56.04
Average Target $76.55
High Target $105.76
Current Price $24.05
Current
$24.05
Target
$76.55
$56.04 $76.55 avg $105.76
Scenario Analysis
Bear Case
$56.04
133.0%
Low target
Base Case
$76.55
+218.3%
Avg target
Bull Case
$105.76
+339.8%
High target
Risk/Reward
2.6x
Favorable
Price in Context
52-Week High
$24.65
-2.4% from high
52-Week Low
$12.58
+91.2% from low
50-Day SMA
$18.67
+28.8% vs SMA
200-Day SMA
$15.96
+50.7% vs SMA
RSI (14)
42.3
Neutral
Target vs 52W High
$76.55
+210.6% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
 Strong Buy 40 78% $257.58 +10.2%
AMGN
Amgen Inc
 Hold 44 50% $190.87 -45.0%
GILD
Gilead Sciences Inc
 Strong Buy 39 82% $362.68 +188.2%
VRTX
Vertex Pharmaceuticals Inc
 Strong Buy 40 83% $438.34 -6.6%
REGN
Regeneron Pharmaceuticals
 Buy 38 71% $76.80 -87.6%
ALNY
Alnylam Pharmaceuticals Inc
 Strong Buy 37 76% $102.31 -64.5%
RVMD
Revolution Medicines Inc
 Strong Buy 27 96% $114.11 -32.3%
NTRA
Natera Inc
 Strong Buy 27 89% $142.91 -39.1%